Macimorelin Acetate Patent Expiration
Macimorelin Acetate is Used for diagnosing adult growth hormone deficiency. It was first introduced by Novo Nordisk Inc
Macimorelin Acetate Patents
Given below is the list of patents protecting Macimorelin Acetate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Macrilen | US8192719 | Methods and kits to diagnose growth hormone deficiency by oral administration of EP 1572 or EP 1573 compounds | Oct 12, 2027 | Novo |
| Macrilen | US6861409 | Growth hormone secretagogues |
Aug 01, 2022
(Expired) | Novo |
Macimorelin Acetate's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List